Adam Gazzaley - Jul 2, 2024 Form 4 Insider Report for Akili, Inc. (AKLI)

Role
Director
Signature
/s/ Jacqueline Studer, attorney-in-fact
Stock symbol
AKLI
Transactions as of
Jul 2, 2024
Transactions value $
$0
Form type
4
Date filed
7/2/2024, 10:28 AM
Previous filing
Dec 13, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction AKLI Common Stock, par value $0.0001 Disposition pursuant to a tender of shares in a change of control transaction -1.09M -100% 0 Jul 2, 2024 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Adam Gazzaley is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may continue.

Explanation of Responses:

Id Content
F1 Reflects disposition of shares of common stock (each, a "Share") of the Issuer at a price per Share of $0.4340 (the "Offer Price") pursuant to the terms of that certain Agreement and Plan of Merger (the "Merger Agreement"), dated as of May 29, 2024, by and among the Issuer, Virtual Therapeutics Corporation, a Delaware corporation ("Parent") and Alpha Merger Sub, Inc., a Delaware corporation and a wholly-owned subsidiary of Parent ("Purchaser"), Purchaser completed a tender offer for shares of common stock of the Issuer and thereafter merged with and into the Issuer, effective as of July 2, 2024 (the "Effective Time") with the Issuer surviving the merger. As of the Effective Time, each Share held by the Reporting Person or his affiliates was converted into the Offer Price.